Becton Dickinson and Co BDX
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1963-09-25 |
| Shares Out. | 275,540,000 |
| Website | bd.com/ ↗ |
| Phone | 12018476800 |
| Employees | 72,000 |
| Revenue | $4.71B |
| Gross Profit | $2.15B |
| Net Income | -$311.0M |
| Free Cash Flow | $3.14B |
| Total Assets | $50.83B |
| Total Liabilities | $26.70B |
| Equity | $24.13B |
About Becton Dickinson and Co
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Becton Dickinson and Co is a publicly traded company under the ticker symbol BDX on the NEW YORK STOCK EXCHANGE, INC., operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-07-01)

